Search company, investor...


Founded Year



Other Investors | Alive

About Kelaroo

The KRMS aims to provide their organization with the tools needed to keep the key ingredients of research at their scientists' fingertips. Using the KRMS, researchers as well as stockroom, purchasing and EH&S personnel readily find, request, receive and track all chemical products. Inventory Management Reagent & Chemical Management for Pharma, BioTech, Manufacturers and Integrators (ELN, ERP, LIMS) Genome mining, sequence profiling and optimization Enhance their bioinformatics discovery program with SeqR. SeqR applies machine learning to public and sequence data to generate models with powerful sequence profiling abilities well suited to genome mining, sequence optimization, and SAR analysis.

Headquarters Location

312 South Cedros Avenue Suite 320

Solana Beach, California, 92075,

United States

Missing: Kelaroo's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: Kelaroo's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Kelaroo Web Traffic

Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

Kelaroo Rank

Kelaroo Frequently Asked Questions (FAQ)

  • When was Kelaroo founded?

    Kelaroo was founded in 2000.

  • Where is Kelaroo's headquarters?

    Kelaroo's headquarters is located at 312 South Cedros Avenue, Solana Beach.

  • What is Kelaroo's latest funding round?

    Kelaroo's latest funding round is Other Investors.

  • Who are the investors of Kelaroo?

    Investors of Kelaroo include Amylin Pharmaceuticals.

  • Who are Kelaroo's competitors?

    Competitors of Kelaroo include Nabsys, DNAnexus, OpGen, HTG Molecular Diagnostics, Aventura HQ and 13 more.

Compare Kelaroo to Competitors


BioInquire,  is a bioinformatics software company engaged in the development and commercialization of software solutions for mining the products of mass spectrometric analyses. Their flagship proteomics software, PROTEOIQ offers a unified software solution that supports the entire proteomic data analysis pipeline, from statistical validation to quantification.

Solidus Biosciences Logo
Solidus Biosciences

Solidus Biosciences is a company that received a STTR Phase II grant for a project entitled: Development of a Lead Optimization Chip for Drug Discovery. Their award is funded under the American Recovery and Reinvestment Act of 2009 and their project will address further development and commercialization of a multi-enzyme lead optimization chip (Multizyme Chip) for high-throughput generation of lead compound analogs coupled with cell-based screening for the rapid identification of biologically active derivatives. Such a capability directly impacts a key bottleneck in drug discovery; namely, the efficient optimization of lead compounds to develop drugs with optimal pharmacological properties. Solidus Biosciences, Inc. proposes to combine six biocatalysis with pharmacological screening to provide rapid identification of biologically active compounds against cell-specific targets, which is a new paradigm for lead optimization. Moreover, the Multizyme Chip platform will be well-suited for lead optimization in related industries, including agrochemicals, cosmetics, and cosmeceuticals. The Solidus technology will thus improve the competitiveness and efficiency of the pharmaceutical, cosmetics, and chemical industries, and will serve as a rich source of new and improved commercial products. The broader impacts of this research are the advances that Solidus Biosciences will achieve toward generating better and safer drugs, reducing the cost to develop these drugs, and increasing the overall efficiency of the pharmaceutical industry. Solidus will generate Multizyme Chips for purchase by pharmaceutical and biotechnology companies to facilitate their lead optimization programs, particularly those involving natural product-derived and complex synthetic small molecule leads. Cryopreservation techniques developed in Phase II will enable the sale of chips and chip-handling devices produced during Phase I, and will allow seamless penetration of the Solidus technology platform into the company's target markets. Solidus Biosciences is a company that received a STTR Phase I grant for a project entitled: Development of a Lead Optimization Chip for Drug Discovery. Their research project aims to develop a new method for generating lead compounds by using enzymatic modification of compound sets. Availability of new methodology to generate biologically active compounds from existing molecules may enhance the success of the drug discovery process and may lead to the discovery of new and useful therapeutics. Solidus Biosciences is a company that received a STTR Phase I grant for a project entitled: High-Throughput RNAi Screening of Mammalian Cells. Their research project aims to develop a system for the rapid screening of siRNAs that can inhibit genes involved in cellular responses such as hyperosmotic stress that can affect pathways of high commercial importance, including protein production. Use of hyperosmotic stress as a proof of concept system will demonstrate the feasibility of high-throughput RNAi screening and will at the same time yield results that can be used to improve monoclonal antibody production in commercial and laboratory settings Production of biopharmaceuticals such as antibodies is exquisitely responsive to the culture conditions under which the cells are grown and thus can be improved through optimizing such settings, which in turn, would affect the genes involved in the specific synthetic pathways of interest. Development of a rapid methodology to identify inhibitory RNA molecules that can inhibit genes that adversely affect yield would be of significant importance to pharmaceutical companies that produce protein therapeutics and may result in a lowering of the const of these therapeutic entities.


SIRS-Lab with its diagnostic portfolio! VYOO Sepsis Test is a multiplex pcr detection kit to identifiy bacteria and fungi in whole blood! LOOXSTER sample preparation kit concentrates bacterial and fungal DNA! With expert knowledge in molecular diagnostic, critical care medicine, microbiology, assay design and gene expression service!

Helix Therapeutics

Helix is pursuing therapies for HIV/AIDS and genetic diseases, such as sickle cell anemia and b-Thalassemia, two of the most common human genetic diseases. The company's technology, developed at the Yale University School of Medicine and licensed exclusively, on a worldwide basis, to Helix, uses patented oligonucleotides that bind to the human genome resulting in permanent, targeted gene modification (TGM). Helix's proprietary TGM technology platform is a chemical genetics approach that uses the cell's own DNA repair machinery to modify permanently human genes in vivo.

Functional Biosciences

Functional Biosciences specializes in genomics research. The company produces reagents and an informatics tools, and aims to provide services that simplify preclinical drug development, reduce the costs of toxicity screening, improve the efficiency of DNA sequencing, and more.


Virmatics is a bioinformatics software company developing efficient, and automated tools for biomedical researchers. Their software aims to give researchers the ability to plan experiments and record, store, and analyze data with unparalleled flexibility. Virmatics has been a member of the incubator since Fall 2004.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.